The FDA recently approved the use of topical ruxolitinib for the management of the most common form of vitiligo which is called nonsegmental vitiligo.

Ruxolitinib is a Janus Kinase inhibitor. JAK inhibitors bind to certain cytokine receptors, resulting in suppression of cytokine and growth factor signalling pathways which are involved in auto-immune diseases. Treatment may need to be continued for 6 months or longer.

Find the full piece on the FDA website.